Orum Therapeutics, a public biotechnology company, has secured $165.0 million in new investment capital. This funding round will support the continued development of the company's innovative TPD2® platform, which focuses on targeted protein degradation therapeutics. Orum Therapeutics specializes in degrader-antibody conjugates (DACs), a novel class of therapies that combine the precision of antibodies with proprietary degrader payloads. These DACs are designed to break down disease-causing proteins within specific cells, aiming to address previously "undruggable" targets and enhance the effectiveness, safety, and reach of targeted protein degradation.
The newly raised capital is intended to accelerate Orum's strategic initiatives, including the advancement of its lead programs, which target GSPT1. Furthermore, the funds will be allocated towards expanding the company's next-generation DAC pipeline and developing proprietary linker technologies. These linker technologies are crucial for increasing the flexibility and precision of future DAC programs, thereby broadening the potential applications of Orum's therapeutic approach. This investment is expected to bolster the company's efforts to bring novel treatments to patients.
This significant capital infusion underscores the potential of Orum's approach to developing first-in-class cancer therapies. With headquarters in Daejeon, South Korea, and Lexington, Massachusetts, U.S., Orum Therapeutics is globally positioned to deliver these innovative treatments. The company remains focused on its mission to improve patient outcomes for those with hard-to-treat diseases by enabling the selective degradation of challenging protein targets, aiming for continued growth and impact in the biotechnology sector.
